The poor prognosis following surgery and radiation treatment of patients with glioblastoma multiforme and other malignant gliomas has led to intensive efforts in the search for alternative therapies (Chang et al., 1983) . More aggressive surgery (Albert et al., 1994) and focused radiotherapy (Mehta et al., 1994) are possibly associated with improved survival but cure is likely to remain elusive with these techniques alone because of the adverse growth characteristics of gliomas (Kelly et al., 1987) . Chemotherapy offers the possibility of entire regional treatment but its impact on glioma therapy has been modest (Fine et al., 1993) . This is due to a number of factors including penetration problems, the intrinsic lack of efficacy of the available agents (Kornblith and Walker, 1988) , the heterogeneity of tumours (Allalunis et al., 1992) and adverse conditions in the associated microenvironment (Rampling et al., 1994) . There is a clear need for alternative therapies.
One approach has been to use viruses, either to deliver a therapeutic gene (Oldfield et al., 1993) or as killing agents in their own right (Martuza et al., 1991) . This latter approach has particular appeal in the central nervous system (CNS) where the proliferative activity of the tumour distinguishes it from the surrounding normal brain which is essentially nonproliferative. Effective viral therapy in rodents based on replication-deficient mutants of herpes simplex virus type 1 (HSV-1) have been described (Mineta et al., 1995) .
Herpes simplex virus is a large double-stranded DNA virus whose genome consists of two unique segments, long and short, each bounded by a set of inverted repeats. The long repeat region of the genome contains a diploid gene, RLI (Chou and Roizman, 1986; Dolan et al., 1992) whose protein product ICP34.5 is a major determinant of pathogenicity (Chou et al., 1990; MacLean et al., 1991; McKie et al., 1994) . We have previously isolated an HSV-1 mutant 1716 which has a 759 bp depletion in both copies of RL1 (MacLean et al., 1991) . This mutant has a markedly attenuated ability to replicate in the CNS following both corneal and footpad inoculation of mice, and has an LD50 106-fold higher than its parental strain 17+ following intracerebral inoculation. In vitro 1716 and other RLI null mutants replicate as efficiently as their parental virus in established dividing cell lines from different species but replicate poorly in non-dividing cells (MacLean et al., 1991; Brown et al., 1994a) .
It has previously been shown in one human neuroblastoma cell line SK-N-SH that mutants which fail to express ICP34.5 grow poorly and are specifically unable to prevent shut-off of cellular protein synthesis (Chou and Roizman, 1992) , whereas infection of Vero cells which are non-neuronal in origin results in sustained protein synthesis and production of infectious progeny. Therefore in cells of neuronal origin ICP34.5 provides a survival mechanism which enables the virus to sustain its replication cycle and produce infectious virus. In the context of brain tumour therapy, RLI deletion mutants have been identified as being of potential use since they should replicate preferentially in tumour cells, which constitute a mass of dividing cells within an otherwise quiescent population, non-permissive for viral replication. RL1 null mutants have the additional advantage in some cell lines that they provide a double hit phenomenon whereby cell killing should occur not only through lysis owing to growth and release of replicating virus, but also by premature shutoff of host cell protein synthesis. However, since the requirement of HSV-1 for ICP34.5 is both cell type-and cell state-specific (Brown et al., 1994a) , it cannot be assumed at this stage that RL1 mutants will provide effective killing of all tumour cell types.
The therapeutic potential of RL1 mutants has so far been assessed in xenograph tumour models in animals (Markert et al., 1993; Chambers et al., 1995; Randazzo et al., 1995) . Of necessity these model systems, although providing important information, cannot mimic the human situation where human heterogeneity and host environment can influence tumour and treatment behaviour. We therefore considered it important to determine whether RL1-negative HSV could kill naturally occurring human CNS tumours. To evaluate the potential efficacy of RL1 deletion mutants in the treatment of malignant glioma we have analysed viral replication in vitro in biopsy material obtained from patients with anaplastic astrocytoma or glioblastoma multiforme. In addition, we have assessed quantitatively the ability of the virus to grow in established human glioma cell lines in vitro. Owing to the inability to establish and grow sufficient numbers of cells, we were unable to obtain cultures of normal human brain tissue in sufficient quantities for comparative growth analysis.
Materials and methods Cells
Baby hamster kidney clone 13 cells ; MacPherson and Stoker, 1962] were propagated in Eagle medium containing twice the normal concentration of vitamins and amino acids, 5% tryptose phosphate broth and 10% (v/v) fetal calf serum (FCS). The established human glioma cell lines used in this study are outlined in Table I Table I gives a summary of the origins of the cell lines established.
Viruses
Virus stocks were grown and titrated on BHK21/C13 cells as previously described (Brown et al., 1973) . The parental HSV-1 strain used in this study was Glasgow strain 17+ (Brown et al., 1973) (Brown et al., 1994a Preliminary experiments were carried out at both high and low multiplicities of infection. Figure 1 shows from infected cells and undergo further rounds of replication, both mutant and wild-type viruses showed similar growth kinetics in all cell lines tested although the final titre of 1716 was reduced compared with the wild-type infection. Several other established human glioma cell lines were tested for their ability to sustain viral replication at high multiplicities of infection (Figure 2 ). These included MCN(X), U-87MG and U-373MG. In both MCN(X) and U-373MG 1716 and 17+ grew efficiently, showing 102_ to 103-fold increases in titre during the exponential phase of growth. In U-87MG cells, 17+ also showed a 102_ to 103-fold increase in titre during the exponential phase of growth, whereas 1716 showed limited replication in this cell line. Interestingly, both viruses failed to replicate in MCX(X) cells (data not shown) and unlike primary tumour cells which were non-permissive for HSV (e.g. BG500) this cell line showed no signs of viral c.p.e.
Growth of wild-type and RLI mutant virus in tumour biopsy material Having established that the RLI-negative mutant virus 1716 can replicate efficiently and destroy established human glioma cell lines in vitro, we wished to determine whether it was also effective in killing tumour cells obtained from patients undergoing cranial surgery. In all cases, cells were passaged as few times as possible to maintain their phenotype and limit selection for a subpopulation of rapidly growing cells. All cells were used at pass numbers between 2 and 4.
A total of nine tumour-derived cell lines from patients diagnosed as having either anaplastic astrocytoma or glioblastoma multiforme were tested for their ability to sustain viral replication. Owing to the limited numbers of cells available, virus growth experiments were only carried out at high multiplicities of infection (Figure 3) . Several 24 h yield experiments were carried out for each cell line, where only the titre of input virus and yield at 24 h after infection were calculated; these demonstrated identical fold increases in titre to those presented in the graphs. In general, both wildtype and mutant virus replication was observed, with increases in titres ranging from 10-fold to 3000-fold during the exponential phase of growth. In one cell line, BG500, 1716 failed to replicate, whereas the titre of 17+ increased -20-fold during the exponential phase of growth. Viral antigen expression in permissive and non-permissive cultures To establish whether lack of 1716 replication in certain cell lines was blocked at a stage before or after viral entry, viral antigen expression was detected by immunofluorescence. We studied BG500 cells, as a representative tumour-derived cell line that was non-permissive for 1716, and MCN(X) the only established glioma cell line tested that was totally nonpermissive for HSV-1. Cell lines that were either fullypermissive (BG398) or semipermissive (BG560) for 1716 replication were used as controls. 1-Cells were infected as described in Materials and methods, fixed 10 h after infection and stained with ZIFi 1, a monoclonal antibody directed against the HSV-1 early protein 65K (Figure 4b and 4d) . The percentage of cells expressing 65K was determined for each cell line. As predicted from the growth experiments, 1716-infected BG398 cultures displayed a higher proportion of antigenpositive cells (79%) than mutant-infected BG560 (48%) or BG500 (34%). In all cultures infected with wild-type virus, 85-95% of cells were infected at this time point and viral yield appeared to be directly related to infectivity. There were no antigen-positive MCN(X) cells in cultures infected with either wild-type virus or 1716, demonstrating that HSV is unable to initiate replication in these cells. Interestingly, MCN(X) cells were also negative for GFAP by immunofluorescence staining.
To determine whether there was a correlation between expression of GFAP and permissivity for HSV-1, the immunofluoresence experiments were repeated and cells were labelled for expression of both GFAP (Figure 4a and c) and 65K. We were unable to demonstrate a correlation between GFAP expression and HSV permissivity, as BG398 cells, which were highly permissive for both wild-type and 1716 replication had a low percentage of GFAP positive cells (14%) whereas BG500 which were non-permissive for 1716, but permissive for 17+ had a high percentage of GFAPexpressing cells (75%). There was no correlation between expression of GFAP in any individual cell and permissivity for HSV, as all cultures contained 65K-positive cells which were either GFAP-positive or GFAP-negative.
Failure of RLI mutants to replicate in some cell lines is caused by premature shut-off of host cell protein synthesis
Having established in BG500 cells that the block in the viral replication cycle is not caused by an inability of the virus to enter the cell, we wished to determine whether the failure to support replication of RL1 mutant virus was due to shut-off of cellular protein synthesis. Three cell lines were selected which varied in their permissivity for 1716: BG398, which was fully permissive; BG560, which was semipermissive; and BG500, which was non-permissive. Figure 5 shows the levels of [35S]methionine incorporated into cells infected with either wild-type or 1716 or uninfected controls.
In fully permissive BG398 cells the levels of cellular protein synthesis are very similar following infection with either wild-type or 1716 at all time points examined although there appears to be a slight decrease in protein synthesis by 8-9 h after infection in cells infected with 1716. In cell lines which are less permissive for 1716 compared with 17+ there are reduced levels of protein synthesis in 1716-infected cells harvested as early as 5-7 h after infection; 9 h after infection, incorporation of [35S]methionine is markedly reduced in BG500 and BG560 cells.
Discussion
Several studies in mice have demonstrated regression of experimentally implanted tumours by replication-compromised variants of herpes simplex virus that replicate normally in dividing cells but fail to replicate in nondividing cells of the nervous system. One of the earliest studies using a thymidine kinase (TK)-negative HSV mutant dlsptk (Coen et al., 1989 ) demonstrated a dose-dependent improvement in survival of nude mice bearing intracranial tumours following intratumoral therapy (Martuza et al., 1991) . However, subsequent studies demonstrated that this mutant is unsuitable for therapeutic use in humans as it can cause encephalitis. (Chou and Roizman, 1990; MacLean et al., 1991; McKie et al., 1994) . A recent study using the Harding -Passey melanoma cell line to establish CNS tumours in C57BI/6 mice demonstrated that stereotactic injection of the avirulent HSV variant 1716 into the tumour 5 -10 days after CNS (MacLean et al., 1991) or immunocompromised SCID mice (Valyi-Nagy et al., 1994) ; a recent study has also demonstrated that an HSV-1 variant containing a mutation in RLI is similarly nonneurovirulent following intracranial inoculation of owl monkeys (Mineta et al., 1995) and we would also predict that RL1 mutants will fail to replicate in the human CNS. Previous studies which have used herpes simplex virus vectors for the treatment of experimentally induced brain tumours have been directed towards the development of relevant in vivo models to study tumour regression and longterm survival. Consequently, these studies have concentrated on cell lines which are known to grow as xenographs in mice (Markert et al., 1993; Chambers et al., 1995) with very little quantitative analysis of viral replication in established CNS tumour cell lines or primary tumour tissue obtained from surgical specimens. If RL1-negative HSV is to be seriously considered as a realistic tumour therapy, it is crucial to ensure that the virus is capable of replicating and killing naturally occurring tumours. Therefore, as a preliminary prerequisite to human therapy, we have evaluated the CNS tumour killing potential of RLI-negative HSV.
With the exception of one cell line, MCN(X), we found that wild-type HSV-1 replicated in all cell lines tested. In general wild-type and mutant virus showed similar replication kinetics in cell lines derived from anaplastic astrocytoma (e.g. G-AST and BG398), but were more variable in cells derived from glioblastoma multiforme (e.g. BG500 and BG560). This could be explained by the heterogeneous pathology of glioblastoma multiforme, which could include populations of refractile cells non-permissive for HSV. Immunofluorescence staining of MCN(X) demonstrated that viral gene expression was not initiated by either wild-type virus or 1716 in these cells and unlike BG500 cells, which were also nonpermissive for 1716, these cells failed to round up and die. The survival of MCN(X) cells following infection supports the double-hit response hypothesis as these cells do not suffer an infection-induced death. The failure of HSV to replicate in this cell line could be owing to the lack of suitable cellular receptors for adsorption and/or penetration or it could be at a stage subsequent to virus entry.
1716 also failed to replicate in one cell line derived from tumour biopsy material. In this case the mutant entered the cell as indicated by expression of the 65K DNA-binding protein yet no infectious virus was produced possibly as a consequence of the shut-off of cellular protein synthesis demonstrated early in infection. However, a limited number of cells did support 1716 replication, a situation similar to that recently demonstrated in 3T6 cells (Brown et al., 1994a) . One possible explanation for this finding is that a proportion of the cells produce a protein which can compensate for the loss of ICP34.5, preventing shut-off of cellular protein synthesis thus allowing viral replication. However the decline in protein synthesis observed in both BG500 and BG560 cells infected with 1716 appeared similar, yet BG500 cells were totally non-permissive for 1716 and a direct correlation cannot be made between viral titre and degree of host cell protein synthesis shut-off-other factors are certainly involved. Variations in expression of proteins which are functionally homologous to ICP34.5 could account for the differences observed in 1716 growth or alternatively the cellular proteins could be totally unrelated. As the cells were infected at high multiplicities of infection, where all cells in the culture would be expected to be infected, a difference in a 1 2 3 4 5 6 CNS U_W Umapy m. HSV-1 EA McKe et a X 751 individual cellular metabolism or protein expression would seem a more likely explanation than a defect in maturation and virus egress preventing further rounds of replication as previously shown in 3T6 (Brown 1994b) .
The finding that not all tumour cells are permissive for 1716 replication is important not only in terms of the biology of HSV but also in its implications for the treatment of human gliomas. At face value it indicates that not all human gliomas could be successfully treated using HSV RLI null mutant therapy. The BG500 cell line was derived from a patient with glioblastoma multiforme, the most commonly found primary tumour of the nervous system. As indicated by the term 'multiforme', the tumour is characterised by a pleomorphic cellular population. Chromosome banding techniques (Bigner et al., 1984 (Bigner et al., , 1986 
